UCB.BR - UCB SA

Brussels - Brussels Delayed Price. Currency in EUR
109.85
-0.15 (-0.14%)
As of 3:58PM CEST. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close110.00
Open108.25
Bid0.00 x 0
Ask0.00 x 0
Day's Range107.45 - 110.90
52 Week Range60.18 - 110.90
Volume298,711
Avg. Volume424,821
Market Cap20.716B
Beta (5Y Monthly)0.53
PE Ratio (TTM)25.97
EPS (TTM)4.23
Earnings DateJul 27, 2020
Forward Dividend & Yield1.24 (1.13%)
Ex-Dividend DateMay 04, 2020
1y Target Est74.54
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • UCB and Ferring Pharmaceuticals Announce Co-Promotion of CIMZIA® (certolizumab pegol) for the Treatment of Adults with Moderate to Severe Crohn's Disease
      PR Newswire

      UCB and Ferring Pharmaceuticals Announce Co-Promotion of CIMZIA® (certolizumab pegol) for the Treatment of Adults with Moderate to Severe Crohn's Disease

      UCB and Ferring Pharmaceuticals Inc. today announced they have entered into a co-promotion agreement to commercialize the prefilled syringe formulation of CIMZIA® (certolizumab pegol) in the United States, specifically for the treatment of Crohn's disease (CD). Ferring will take over marketing, sales promotion, and field medical affairs activities. UCB will continue to be responsible for all product-related activities, including revenue recognition. CIMZIA is an injectable biologic treatment option for adults with moderate to severe Crohn's disease with inadequate response to conventional therapy. UCB will continue to promote and to commercialize the lyophilized formulation of CIMZIA for all indications as well as the prefilled syringe formulation for CIMZIA's rheumatology and dermatology indications.

    • First Presentations of Bimekizumab Phase 3 Data Demonstrate Superior Skin Clearance Over Placebo and Stelara® at Week 16 in Adults with Moderate-to-Severe Plaque Psoriasis
      PR Newswire

      First Presentations of Bimekizumab Phase 3 Data Demonstrate Superior Skin Clearance Over Placebo and Stelara® at Week 16 in Adults with Moderate-to-Severe Plaque Psoriasis

      UCB, a global biopharmaceutical company, today announced the first presentations of data from the Phase 3 clinical development program of bimekizumab, its investigational IL-17A and IL-17F inhibitor, as part of a virtual session for the American Academy of Dermatology (AAD) 2020 Annual Meeting. Patients treated with bimekizumab achieved superior skin clearance in both the BE VIVID and BE READY Phase 3 studies, compared to those who received placebo or Stelara® (ustekinumab).1,2 The majority of bimekizumab-treated patients in both studies achieved total skin clearance at week 16 and maintained their response for a year, as measured by the Psoriasis Area and Severity Index (PASI) 100 and Investigator Global Assessment (IGA) response of 0.1,2

    • UCB Acquires Engage Therapeutics: Staccato® Alprazolam - A potential Solution for Acute On-demand Seizure Management for People Living With Epilepsy
      PR Newswire

      UCB Acquires Engage Therapeutics: Staccato® Alprazolam - A potential Solution for Acute On-demand Seizure Management for People Living With Epilepsy

      UCB announced today the acquisition of Engage Therapeutics, Inc. (Summit, N.J. (U.S.)), a clinical-stage pharmaceutical company developing Staccato® Alprazolam for the rapid termination of an active epileptic seizure, for US$ 125 million in cash (subject to certain adjustments) and up to US$ 145 million in further potential milestone payments related to clinical development, submission and launch of Staccato® Alprazolam.

    • Why Dividend Hunters Love UCB SA (EBR:UCB)
      Simply Wall St.

      Why Dividend Hunters Love UCB SA (EBR:UCB)

      Is UCB SA (EBR:UCB) a good dividend stock? How can we tell? Dividend paying companies with growing earnings can be...

    • UCB's General Meeting of Shareholders
      PR Newswire

      UCB's General Meeting of Shareholders

      On 9 April 2020, the Belgian Government has published the Royal Decree n°4 of 9 April 2020 on various provisions regarding legislation on co-ownership and companies and associations, in the framework of the fight against the Covid-19 pandemic (the 'Royal Decree'). The Royal Decree entered into force retroactively as of 1 March 2020 and allows for exceptional measures to be taken with respect to general meetings which have been or must be convened before 3 May 2020.

    • Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly
      Simply Wall St.

      Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

      Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

    • UCB Completes the Acquisition of Ra Pharmaceuticals - to Deliver Differentiated Therapies to Patients
      PR Newswire

      UCB Completes the Acquisition of Ra Pharmaceuticals - to Deliver Differentiated Therapies to Patients

      UCB today announced that the acquisition of Ra Pharmaceuticals, Inc. has been successfully completed and Ra Pharma is now a wholly-owned subsidiary of UCB. The former Ra Pharma shareholders received US$ 48 in cash for each Ra Pharma share held at closing.

    • GlobeNewswire

      UCB SA/NV : Convening notice to the general meeting of shareholders

      The Board of Directors invites the shareholders for the Ordinary and Extraordinary General Meeting of Shareholders (the “General Meeting”) which will be held on Thursday, 30 April 2020, at 11:00 am CEST, at the registered office of UCB SA/NV, Allée de la Recherche 60 - 1070 Brussels, for the purpose of considering and voting on the items shown on the agenda set out below. Due to the evolution of the crisis of the Corona virus (Covid-19) and the measures taken by our governments and public authorities, it is likely that UCB SA/NV will not be able to allow physical access to its General Meeting of 30 April 2020.

    • Read This Before You Buy UCB SA (EBR:UCB) Because Of Its P/E Ratio
      Simply Wall St.

      Read This Before You Buy UCB SA (EBR:UCB) Because Of Its P/E Ratio

      This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...

    • Thomson Reuters StreetEvents

      Edited Transcript of UCB.BR earnings conference call or presentation 20-Feb-20 1:00pm GMT

      Full Year 2019 Ucb SA Earnings Call

    • Reuters

      Drug pricing review group signs deal with Aetion for patient data

      The Institute for Clinical and Economic Review (ICER), a small but influential Boston-based research group, has signed a deal with private technology company Aetion to help it use patient health data in its reports on whether individual drugs are priced properly. Large national regulators, including the U.S. Food and Drug Administration and United Kingdom's National Institute for Health and Care Excellence (NICE), are considering increasing the use of data gathered outside of clinical trials on the effectiveness of treatments, often referred to as real-world data. The FDA is running a pilot project using Aetion's database of insurance claims to replicate clinical trial results, as part of a requirement to comply with healthcare legislation called the 21st Century Cures Act.

    • The UCB (EBR:UCB) Share Price Is Up 27% And Shareholders Are Holding On
      Simply Wall St.

      The UCB (EBR:UCB) Share Price Is Up 27% And Shareholders Are Holding On

      By buying an index fund, investors can approximate the average market return. But if you choose individual stocks with...

    • PR Newswire

      UCB: Osteoporosis Patients Believe Their Condition is Neglected and Deprioritised by Healthcare Authorities

      Results from a new UCB survey have revealed the impact osteoporosis has on women, with nearly two thirds (65%) agreeing that their condition is being neglected and that their healthcare authority should be doing more to prioritise it (83%).1

    • European Commission Approves EVENITY® (romosozumab) For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
      PR Newswire

      European Commission Approves EVENITY® (romosozumab) For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture

      Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the European Commission (EC) has granted marketing authorization for EVENITY® (romosozumab) for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture. EVENITY is a novel bone-builder with a dual effect that increases bone formation and to a lesser extent reduces bone resorption (or bone loss).

    • UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting
      PR Newswire

      UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting

      UCB, a global biopharmaceutical company, today announced positive results from a Phase II study (TP0001; NCT02718716) of its novel, first-in-class subcutaneous (SC, under the skin) monoclonal antibody, rozanolixizumab, in patients with primary immune thrombocytopenia (ITP). The data were presented during an oral presentation today at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida.

    • Reuters

      Belgium's UCB says psoriasis drug beats AbbVie's Humira in trial

      UCB SA said on Friday its experimental plaque psoriasis drug produced better results compared to AbbVie Inc's blockbuster drug, Humira, in reducing the severity of the disease. UCB's drug, bimekizumab, also met the main goal of clearing or almost clearing the skin of plaques or rashes in a late-stage study, as assessed by an investigator, according to the Belgium-based company. AbbVie's Humira is the world's top selling drug and treats rheumatoid arthritis and psoriasis.

    • Bimekizumab Phase 3 Psoriasis Study Demonstrates Superiority Versus Humira®
      PR Newswire

      Bimekizumab Phase 3 Psoriasis Study Demonstrates Superiority Versus Humira®

      Regulated Information – Inside Information – UCB, a global biopharmaceutical company, today announced positive results from the Phase 3 active-controlled BE SURE study. BE SURE compared the investigational IL-17A and IL-17F inhibitor bimekizumab to the TNF inhibitor adalimumab in the treatment of adults with moderate-to-severe plaque psoriasis. BE SURE met its co-primary endpoints at week 16, demonstrating superiority of bimekizumab to adalimumab in achieving at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) and Investigator Global Assessment (IGA) response of clear or almost clear (IGA 0/1).1

    • UCB Presents New Data Demonstrating Commitment to Epilepsy at 2019 American Epilepsy Society Meeting
      PR Newswire

      UCB Presents New Data Demonstrating Commitment to Epilepsy at 2019 American Epilepsy Society Meeting

      UCB today announced 14 posters have been selected for presentation at this year's American Epilepsy Society Meeting, taking place in Baltimore, Maryland, December 6-10. The UCB scientific program includes the presentation of clinical data describing BRIVIACT® (brivaracetam) CV, VIMPAT® (lacosamide) CV, and NAYZILAM® (midazolam) Nasal Spray CIV, now available in the U.S. for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older.1 Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.

    • UCB Announces availability of NAYZILAM® (midazolam) Nasal Spray CIV, the first and only nasal rescue treatment for seizure clusters in the U.S.
      PR Newswire

      UCB Announces availability of NAYZILAM® (midazolam) Nasal Spray CIV, the first and only nasal rescue treatment for seizure clusters in the U.S.

      UCB announced today that NAYZILAM® (midazolam) nasal spray CIV will be available in retail pharmacies on December 2, 2019, for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older.1

    • An Intrinsic Calculation For UCB SA (EBR:UCB) Suggests It's 29% Undervalued
      Simply Wall St.

      An Intrinsic Calculation For UCB SA (EBR:UCB) Suggests It's 29% Undervalued

      Does the November share price for UCB SA (EBR:UCB) reflect what it's really worth? Today, we will estimate the stock's...

    • PR Newswire

      Bimekizumab Positive Results Confirmed in Second Phase 3 Psoriasis Study

      BRUSSELS, Nov. 15, 2019 /PRNewswire/ -- Regulated Information – Inside Information – UCB, a global biopharmaceutical company, today announced positive results from BE READY, the second of three Phase 3 studies this year to report findings on the investigational treatment bimekizumab.1 BE READY evaluated the efficacy and safety of the IL-17A and IL-17F inhibitor bimekizumab in the treatment of adults with moderate-to-severe plaque psoriasis.

    • PR Newswire

      UCB Presents New Data From Rheumatology Portfolio Addressing Unmet Needs in Axial Spondyloarthritis, Psoriatic Arthritis and Lupus at 2019 ACR/ARP

      - Oral presentations include data on improvements in clinical and patient-reported outcomes with early CIMZIA (certolizumab pegol) treatment in non-radiographic axial spondyloarthritis, and a reduction ...

    • How Should Investors React To UCB SA's (EBR:UCB) CEO Pay?
      Simply Wall St.

      How Should Investors React To UCB SA's (EBR:UCB) CEO Pay?

      Jean-Christophe Tellier became the CEO of UCB SA (EBR:UCB) in 2015. This report will, first, examine the CEO...

    • EVENITY® (Romosozumab) Receives Positive CHMP Opinion For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
      PR Newswire

      EVENITY® (Romosozumab) Receives Positive CHMP Opinion For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture

      THOUSAND OAKS, Calif. and BRUSSELS, Oct. 17, 2019 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced that following a re-examination procedure, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending Marketing Authorization for EVENITY® (romosozumab) for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture and with no history of myocardial infarction or stroke. EVENITY is a novel bone-builder with a dual effect that increases bone formation and to a lesser extent reduces bone resorption (or bone loss).

    • PR Newswire

      Bimekizumab Phase 3 Psoriasis Study Meets All Endpoints, Achieving Significantly Greater Efficacy Versus Placebo and Ustekinumab

      BRUSSELS, Oct. 17, 2019 /PRNewswire/ -- Regulated Information - Inside Information - UCB, a global biopharmaceutical company, today announced positive results from BE VIVID, the first of three Phase 3 studies evaluating the efficacy and safety of bimekizumab, an IL-17A and IL-17F inhibitor, in the treatment of adults with moderate-to-severe chronic plaque psoriasis. The safety and efficacy of bimekizumab has not been established and it is not approved by any regulatory authority worldwide.